{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:45Z","timestamp":1761710145407,"version":"3.41.2"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21Y11901700","ZD2021CY001"],"award-info":[{"award-number":["21Y11901700","ZD2021CY001"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC3044600"],"award-info":[{"award-number":["2024YFC3044600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sivelestat sodium, an inhibitor of neutrophil elastase, was broadly used in the treatment of severe pneumonia. However, the pharmacokinetic (PK) characteristics of sivelestat in patients with severe pneumonia were still unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To understand the PK characteristics of sivelestat for optimizing the dose in Chinese patients with severe pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we enrolled 15 participants who received sivelestat 300\u2013500\u2009mg every 24\u2009h with an infusion duration of 5 to 14\u2009days. Blood samples of 48 were collected and separated for plasma drug concentration detection by an ultra\u2010high\u2010performance liquid chromatography\/tandem mass spectrometry. A population pharmacokinetic (PPK) analysis of sivelestat was performed using a monolix2024R1 software. A Monte Carlo simulation was conducted to assess various dosing schedules and varying covariate levels within the desired therapeutic drug\u2010monitoring concentration range (C<jats:sub>min,ss<\/jats:sub> 8\u201312\u2009mg\/L).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patients had a mean age of 65\u2009years (range, 35\u201387), with 2 females and 13 males. These data were best described by a one\u2010compartment model with proportional residual error. The apparent distribution volume and apparent clearance (CL) of sivelestat were 20.88\u00a0L and 1.79\u00a0L\/h, respectively. The clearance of sivelestat is influenced by the covariate total bilirubin (TBIL), prompting a recommendation for a reduced dose in patients with elevated TBIL levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, our findings suggest that the CL\/F in patients with severe pneumonia is similar to that in healthy individuals. TBIL can affect CL\/F of sivelestat; therefore, TBIL\u2010based dosing regimens provide a practical strategy for achieving sivelestat therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/fcp.70001","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:05:28Z","timestamp":1739232328000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics of sivelestat in Chinese patients with severe pneumonia"],"prefix":"10.1111","volume":"39","author":[{"given":"Xiaolin","family":"Zhang","sequence":"first","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiliang","family":"Hu","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziran","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Bioengineering &amp; Therapeutic Sciences University of California San Francisco  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Pan","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqin","family":"Mao","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-268X","authenticated-orcid":false,"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30925\u20109"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010021\u201000259\u20100"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328326f571"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102021\u2010065871"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.04.003"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31550\u20106"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128107"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2019.10.009"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)60733\u20104"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3045"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6710278"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201011\u2010844530"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11\u20103273"},{"issue":"10","key":"e_1_2_15_15_1","first-page":"793","article-title":"Efficacy of sivelestat for acute lung injury due to severe bacterial pneumonia with systemic inflammatory response syndrome","volume":"46","author":"Nakamura S","year":"2008","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.01.037"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2012.08.005"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113876"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106723"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2016.02.003"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12611"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101523"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.95454"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.517"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.07.021"},{"issue":"3","key":"e_1_2_15_27_1","first-page":"495","article-title":"Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population","volume":"66","author":"Guzek M","year":"2012","journal-title":"Przegl Epidemiol"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:21:28Z","timestamp":1743319288000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/fcp.70001"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70001","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"type":"print","value":"0767-3981"},{"type":"electronic","value":"1472-8206"}],"subject":[],"published":{"date-parts":[[2025,2,9]]},"assertion":[{"value":"2024-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70001"}}